Doxycycline is an antibacterial drug is derived from oxytetracycline and is available as doxycycline hyclate. Doxycycline hyclate is used in the treatment of many bacterial infections such as acne, urinary tract infection, intestinal infections, respiratory infections, eye infections, gonorrhea, syphilis, and others. Moreover, these drugs can be used to treat blemishes and bums caused by rosacea. Generally doxycycline hyclate is not prescribed to lactating & breastfeeding patients. Doxycycline hyclate is also not prescribed to children below 8 years because of it can cause permanent yellowing of their teeth unless it is a life threatening condition such as anthrax.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the oral doxycycline hyclate market.
Top Impacting Factors
- Surge in cases of bacterial infections such as urinary tract infection, pneumonia, & respiratory diseases, rise in hospital acquired infections, increase in demand home based treatment, surge in demand for treatment of anthrax, and rise in unhygienic practices are the key factors that drive the growth of the market.
- In addition, surge in demand for minimally invasive treatment procedure, rise in awareness regarding treatment of bacterial infections, increase in demand for cost effective treatment, surge in expenses on health care sector, advantages associated with this drug such as high effectiveness, R&D activities to improve quality of drug, and launch of novel drugs are expected to boost the growth of the market.
- However, adverse effects related to doxycycline drugs and presence of alternative treatments can hinder the growth of the market.
- Contrarily, government initiatives for regulatory approvals and spreading awareness regarding bacterial infection treatment are expected to offer lucrative opportunities for the expansion of the market.
Market Trends
New Product Launches to Flourish the Market
In 2020, Alembic Pharma announced U.S. FDA permission launch of generic doxycycline hyclate tablets. This product is generic version of Almirall tablet. This tablet can be used in treatment of bacterial infection.
In 2018, Lupin announced launch of doxycycline hyclate tablet USP 100 mg in U.S. Company received U.S. FDA approval for launch of tablet and this tablet used in treatment of acne & bacterial infections.
Key Benefits of the Report
- This study presents the analytical depiction of oral doxycycline hyclate market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Oral Doxycycline Hyclate Market Report
- Which are the leading players active in the oral doxycycline hyclate market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "oral doxycycline hyclate"?
- What is "oral doxycycline hyclate" market prediction in the future?
- Who are the leading global players in the "oral doxycycline hyclate" market?
- What are the current trends and predicted trends?
- What are the key benefits of the "oral doxycycline hyclate" market report?
Oral Doxycycline Hyclate Market, by Product Type Report Highlights
| Aspects | Details |
 By Product Type |
|
 By Application |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Ajanta Pharma, Mayne Pharma, Alembic Pharmaceuticals, Amneal Pharmaceuticals, Sun Pharmaceutical, Almirall, Zydus Pharmaceuticals, Mylan, Teva, Emcure, Prinston Pharmaceutical, G&W Laboratories, Heritage Pharmaceuticals, Par Pharmaceutical, Novel Laboratories |
Loading Table Of Content...
